Neurocrine Biosciences (NBIX) Stock Price, Quote, News & History | Benzinga

SPY769.64+0.08%QQQ719.52+0.26%BTC/USD83,243.19+0.37%DIA523.73−0.12%GLD377.26−0.10%TLT79.93−0.25%

Neurocrine Biosciences Inc (NBIX) Stock Price, Quote, News & History

NBIXNASDAQ

Trade with Public

Trade with Public

$142.00

5.023.66%

Last update: Oct 20, 4:23 PM

$141.50

4.523.3%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$142.00

Volume / Avg.

0 / 1.31M

Day Range

- - -

52 Wk Range

122.14 - 186.12

Market Cap

$14.23B

P/E Ratio

20.77

Dividend Yield

-

Exchange

NASDAQ

RSI

37

Short Interest

7.58%

Days to Cover

3.97

Recent Neurocrine Biosciences, Inc. News

Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'

Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported better-than-expected earnings. Rockwell Automation and Neurocrine Biosciences had mixed reactions from analysts. Uber and Amcor shares fell, while Tanger, Rockwell Automation, and Neurocrine Biosciences shares all had varying degrees of movement.

Avi Kapoor

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi syndrome prompt caution.

Vandana Singh

Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets under management climbed to $476 million.

Chandrima Sanyal

Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.

Avi Kapoor

Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market

Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

898.10M

Investing Cash Flow (TTM)

-891.20M

Financing Cash Flow (TTM)

60.20M

Free Cash Flow (TTM)

870.40M

Capital Expenditure (TTM)

-27.70M

Net Change in Cash (TTM)

67.10M

Analyst Trends and Forecast

2

Jun

12

2

Jul

3

1

Aug

3

1

Sep

2

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$14.45B

PE Ratio (TTM)

20.77

PE Ratio (FWD)

14.47

PEG Ratio (TTM)

0.29

PS Ratio (TTM)

4.36

PB Ratio (TTM)

3.91

Earnings Yield % (TTM)

4.82%

Earnings Yield % (FWD)

6.91%

EV / EBITDA (TTM)

15.68

Price / EBITDA (TTM)

15.95

Price / Free Cash Flow (TTM)

16.89

Book Value / Share

$36.34

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$600.00M

Total Cash

$332.40M

Debt to Equity

0.11

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

-$600.00M